Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib targeted therapy for pediatric posterior fossa group A (PFA) ependymoma
ChiCTR2100051395Phase 4Recruiting
- Sponsor
- Children's Hospital of Fudan University
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of niraparib in ependymoma (2 arms), sponsored by Children's Hospital of Fudan University. Primary endpoint: Progression-free survival. Started Oct 2021; status: recruiting.
02
Drugs
niraparib
03
Conditions
ependymoma
Beyond the preview
Go deeper on ChiCTR2100051395.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100051395.